Home > News > Midatech nanoparticles heading for the clinic in Q1 2008
May 14th, 2007
Midatech nanoparticles heading for the clinic in Q1 2008
Midatech, the UK group exploring the therapeutic and diagnostic applications of nanoparticles as drug delivery vehicles, scaffolds for synthetic vaccines or antibiotics and non-invasive imaging agents, aims to put its first product into clinical trials in the first quarter of 2008.
This will be multivalent antibiotics delivered on nanoparticles, said Midatech's Storme Thornicroft. The group's listed pipeline includes a project coded MTL 201 that involves antibiotics for the treatment of the 'superbug' methicillin-resistant Staphylococcus aureus (MRSA).
Taking the guesswork out of cancer therapy: New molecular test kit predicts patientís survival and drug response August 1st, 2014
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014
New imaging agent provides better picture of the gut July 30th, 2014
Zenosense, Inc. July 29th, 2014
Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014
President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014
Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014
Air Forceís 30-year plan seeks 'strategic agility' August 1st, 2014